Cargando…

Low-Dose Mepolizumab Effectiveness in Patients Suffering From Eosinophilic Granulomatosis With Polyangiitis

Eosinophilic granulomatosis with polyangiitis (EGPA) is a vasculitis characterized by multisystemic manifestations including asthma. Mepolizumab (300 mg/4 weeks) has recently been approved for EGPA. However, real-life data are scarce and report experiences with high doses of mepolizumab intravenousl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vultaggio, Alessandra, Nencini, Francesca, Bormioli, Susanna, Vivarelli, Emanuele, Dies, Laura, Rossi, Oliviero, Parronchi, Paola, Maggi, Enrico, Matucci, Andrea
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Academy of Asthma, Allergy and Clinical Immunology; The Korean Academy of Pediatric Allergy and Respiratory Disease 2020
Materias:	Brief Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7346991/ https://www.ncbi.nlm.nih.gov/pubmed/32638567 http://dx.doi.org/10.4168/aair.2020.12.5.885

Ejemplares similares

Drug-specific Treg cells are induced during desensitization procedure for rituximab and tocilizumab in patients with anaphylaxis
por: Vultaggio, Alessandra, et al.
Publicado: (2021)

Efficacy and Safety of Mepolizumab (Anti-Interleukin-5) Treatment in Gleich’s Syndrome
por: Matucci, Andrea, et al.
Publicado: (2018)

Mechanisms of Drug Desensitization: Not Only Mast Cells
por: Vultaggio, Alessandra, et al.
Publicado: (2020)

Rapid clinical improvement of atopic dermatitis in an Omalizumab treated patient
por: Bormioli, Susanna, et al.
Publicado: (2019)

Asthma and Chronic Rhinosinusitis: How Similar Are They in Pathogenesis and Treatment Responses?
por: Matucci, Andrea, et al.
Publicado: (2021)

Mepolizumab for Eosinophilic Granulomatosis With Polyangiitis: A European Multicenter Observational Study
por: Bettiol, Alessandra, et al.
Publicado: (2021)

Safety and Efficacy of Mepolizumab in Patients with Eosinophilic Granulomatosis with Polyangiitis
por: Pradhan, Ravi Ranjan, et al.
Publicado: (2019)

Pharmacogenetic investigation of efficacy response to mepolizumab in eosinophilic granulomatosis with polyangiitis
por: Condreay, Lynn D., et al.
Publicado: (2020)

Mepolizumab therapy improves endomyocarditis in seropositive eosinophilic granulomatosis with polyangiitis
por: Wang, Chrong-Reen, et al.
Publicado: (2022)

T Cell Response to Infliximab in Exposed Patients: A Longitudinal Analysis
por: Pratesi, Sara, et al.
Publicado: (2019)

EGPA Phenotyping: Not Only ANCA, but Also Eosinophils
por: Matucci, Andrea, et al.
Publicado: (2023)

Concurrent Use of Mepolizumab and Rituximab for Eosinophilic Granulomatosis With Polyangiitis and Multisystem Involvement
por: Afiari, Agura, et al.
Publicado: (2020)

Effectiveness and safety of mepolizumab in combination with corticosteroids in patients with eosinophilic granulomatosis with polyangiitis
por: Ueno, Masanobu, et al.
Publicado: (2021)

Successful Treatment With Mepolizumab for Eosinophilic Granulomatosis With Polyangiitis: A Case Report
por: Toscano Peña, Andrés, et al.
Publicado: (2023)

Real-world characteristics of “super-responders” to mepolizumab and benralizumab in severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis
por: Portacci, Andrea, et al.
Publicado: (2023)

A Pediatric Case of Relapsing Eosinophilic Granulomatosis with Polyangiitis Successfully Treated with Mepolizumab
por: Nara, Mizuho, et al.
Publicado: (2019)

Successful treatment with benralizumab in a patient with eosinophilic granulomatosis with polyangiitis refractory to mepolizumab
por: Menzella, Francesco, et al.
Publicado: (2021)

Successful Treatment with Mepolizumab for Coronary Spastic Angina Associated with Eosinophilic Granulomatosis with Polyangiitis
por: Takigawa, Yuki, et al.
Publicado: (2023)

Baseline Eosinophil Count as a Potential Clinical Biomarker for Clinical Complexity in EGPA: A Real-Life Experience
por: Matucci, Andrea, et al.
Publicado: (2022)

Mepolizumab therapy in a pediatric patient with eosinophilic granulomatosis with polyangiitis associated with refractory myocarditis
por: Ulu, Kadir, et al.
Publicado: (2022)

Clinical Benefit of Mepolizumab in Eosinophilic Granulomatosis With Polyangiitis for Patients With and Without a Vasculitic Phenotype
por: Terrier, Benjamin, et al.
Publicado: (2023)

Characteristics and Disease Burden of Patients With Eosinophilic Granulomatosis With Polyangiitis Initiating Mepolizumab in the United States
por: Silver, Jared, et al.
Publicado: (2023)

Strategies Targeting Type 2 Inflammation: From Monoclonal Antibodies to JAK-Inhibitors
por: Matucci, Andrea, et al.
Publicado: (2021)

Long-term mepolizumab treatment reduces relapse rates in super-responders with eosinophilic granulomatosis with polyangiitis
por: Masumoto, Nami, et al.
Publicado: (2023)

Mepolizumab as the first targeted treatment for eosinophilic granulomatosis with polyangiitis: a review of current evidence and potential place in therapy
por: Faverio, Paola, et al.
Publicado: (2018)

Eosinophilic Granulomatosis with Polyangiitis
por: Shukla, Ratnakar, et al.
Publicado: (2022)

A Case of Effective Mepolizumab Induction Therapy for Severe Eosinophilic Granulomatosis with Polyangiitis Diagnosed by Eosinophilic Cholecystitis and Interstitial Nephritis
por: Hattori, Keita, et al.
Publicado: (2021)

Safety and effectiveness of mepolizumab therapy in remission induction therapy for eosinophilic granulomatosis with polyangiitis: a retrospective study
por: Ueno, Masanobu, et al.
Publicado: (2022)

Effective treatment with mepolizumab in a patient with severe eosinophilic granulomatosis with polyangiitis complicated with small intestine perforation
por: Sato, Mari, et al.
Publicado: (2023)

How to Prevent and Mitigate Hypersensitivity Reactions to Biologicals Induced by Anti-Drug Antibodies?
por: Vultaggio, Alessandra, et al.
Publicado: (2021)

COVID-19 and eosinophilic granulomatosis with polyangiitis or COVID-19 mimicking eosinophilic granulomatosis with polyangiitis?
por: Özdemir, Bahar, et al.
Publicado: (2021)

Improvement of peripheral neuropathy in a patient with antineutrophil cytoplasmic antibody-negative eosinophilic granulomatosis with polyangiitis by additional mepolizumab
por: Kai, Yoshiro, et al.
Publicado: (2022)

Eosinophilic Granulomatosis with Polyangiitis: An Overview
por: Gioffredi, Andrea, et al.
Publicado: (2014)

Prevasculitic Eosinophilic Granulomatosis With Polyangiitis
por: Burtson, Kathryn M, et al.
Publicado: (2021)

Eosinophilic Variant of Granulomatosis With Polyangiitis
por: Fernandes, Rui L, et al.
Publicado: (2023)

Correction to: COVID-19 and eosinophilic granulomatosis with polyangiitis or COVID-19 mimicking eosinophilic granulomatosis with polyangiitis?
por: Özdemir, Bahar, et al.
Publicado: (2021)

Eosinophilic Cholecystitis Associated with Eosinophilic Granulomatosis with Polyangiitis
por: Ito, Hiroyuki, et al.
Publicado: (2020)

A rare case report of polyangiitis overlap syndrome: granulomatosis with polyangiitis and eosinophilic granulomatosis with polyangiitis
por: Quan, Michele V., et al.
Publicado: (2018)

Eosinophilic Granulomatosis With Polyangiitis: Dissecting the Pathophysiology
por: Fagni, Filippo, et al.
Publicado: (2021)

Renal Involvement in Eosinophilic Granulomatosis With Polyangiitis
por: Doreille, Alice, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_93m1e3nn77dkcv53r6n65ij4mo